Clinical Trial Search

Primary: Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase. — 7.24; 7.17; 2.57; 2.56 Units on a scale — p=.0104

Primary: Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3 — 888.0; 1139; 814.9; 814.5 Geometric Mean Titer (GMT) — p=<0.001

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I — 84.2 meters

Primary: Number of Participants Who Experienced an Adverse Event — 44; 44 Participants

Primary: Overall Survival (OS) — 7.23; 9.43 Months — p=0.28

Primary: Analgesic Effect as Assessed by Brief Pain Inventory (BPI) Item 5 Score (Pain on Average) — 6.4; 6.4; 6.5; 6.6 units on a scale — p=0.1212

Primary: Number of Participants With the Indicated Drug-related Adverse Events — 93; 46; 170; 19 participants

Primary: Overall Survival — 21.7; 25.8 Months — p=0.032

Primary: Hemoglobin A1c (HbA1c) Change From Baseline to Week 52 — 7.46; 7.53; 6.74; 6.71 Percent

Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants

Primary: Overall Time to Disease Progression — 10.9; 9.9 Weeks — p=0.719

Primary: Participants Who Experienced at Least One Adverse Event — 34 participants

Primary: Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial…

Primary: Change in Glycosylated Hemoglobin (HbA1c) — -0.84; -0.10 Percentage — p=<0.001